奥赛康(002755) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 reached ¥448,492,136.86, representing a 32.47% increase compared to ¥338,557,552.24 in the same period last year [26]. - Net profit attributable to shareholders was ¥31,544,742.35, a significant turnaround from a loss of ¥68,591,234.11, marking a 145.99% improvement [26]. - Net profit for the current period was ¥26,431,563.79, a significant recovery from a net loss of ¥75,383,018.82 in the previous period [44]. - The company achieved an operating profit of ¥27,804,099.63, a turnaround from an operating loss of ¥71,462,016.21 in the previous period [44]. - The total profit for the current period was ¥28,800,104.97, recovering from a total loss of ¥71,345,818.60 in the previous period [44]. Assets and Liabilities - The total assets of Beijing Ausun Pharmaceutical Co., Ltd. reached RMB 3,686,481,889.13, an increase from RMB 3,523,881,824.92 in the previous quarter, reflecting a growth of approximately 4.63% [16]. - The company's total liabilities amounted to RMB 650,798,971.30, up from RMB 513,199,460.61, indicating a significant increase of about 26.83% [16]. - The total non-current assets amounted to RMB 1,361,171,691.95, compared to RMB 1,337,400,393.04 in the previous quarter, reflecting an increase of approximately 1.77% [16]. - The total owner's equity increased to RMB 3,035,682,917.83 from RMB 3,010,682,364.31, representing a growth of about 0.83% [18]. Cash Flow - The net cash flow from operating activities was ¥198,390,225.98, compared to a negative cash flow of ¥110,779,210.22 in the previous year, reflecting a 279.09% increase [26]. - Operating cash flow generated from operating activities was $198,390,225.98, a significant improvement compared to a negative cash flow of $110,779,210.22 in the previous period [45]. - Total cash inflow from operating activities was $568,819,881.09, while total cash outflow was $370,429,655.11, resulting in a net cash flow from operating activities of $198,390,225.98 [45]. - The net increase in cash and cash equivalents was $117,692,902.19, compared to a decrease of $26,759,692.05 in the previous period [46]. - The ending balance of cash and cash equivalents reached $1,153,337,238.95, up from $733,916,547.39 at the end of the previous period [46]. Shareholder Information - The equity attributable to the owners of the parent company was RMB 2,911,060,054.36, slightly up from RMB 2,899,985,004.21, showing a growth of approximately 0.39% [18]. - The company reported a total of 19,220 preferred shareholders at the end of the reporting period [10]. - Basic and diluted earnings per share improved to ¥0.03 from a loss of ¥0.07, representing a 142.86% increase [26]. - The company reported a basic earnings per share of ¥0.03, compared to a loss per share of ¥0.07 in the previous period [44]. Expenses and Costs - Total operating costs decreased to ¥429,181,894.86 from ¥431,430,413.60, showing a slight reduction of about 0.5% [38]. - Research and development expenses decreased by 48.09% to ¥63,512,044.42 from ¥122,347,542.93, indicating a strategic optimization in R&D spending [29]. - Research and development expenses decreased to ¥63,512,044.42 from ¥122,347,542.93, indicating a reduction of approximately 48% [38]. - Cash paid for purchasing goods and services was $60,344,062.91, an increase from $42,674,901.31 in the prior period [45]. - Cash paid to employees decreased to $67,101,021.21 from $84,693,510.70, indicating a reduction in labor costs [45]. Other Financial Metrics - The company reported a significant increase in other payables, which rose to RMB 380,481,741.69 from RMB 210,528,776.20, an increase of approximately 80.69% [16]. - Other payables increased by 80.73% to ¥380,481,741.69, primarily due to an increase in product warranty deposits received [29]. - The company received government subsidies amounting to ¥2,337,820.44, which positively impacted its financial performance [26]. - Other comprehensive income after tax was reported at -¥1,900,337.26, compared to a positive amount of ¥6,022,358.68 in the previous period [44]. - The company recorded a tax expense of ¥2,368,541.18, down from ¥4,037,200.22 in the previous period [44]. Future Outlook - The company plans to continue expanding its market presence and product offerings, leveraging the positive financial results to support future growth initiatives [26]. - The company plans to implement new accounting standards starting from 2024, which may impact future financial reporting [42].